Skip to main content
Article thumbnail
Location of Repository

Impact of wastage on single and multi-dose vaccine vials: implications for introducing pneumococcal vaccines in developing countries.

By Divya Parmar, Elaine M Baruwa, Patrick Zuber and Souleymane Kone


Introduction: Pneumococcal conjugate vaccines are expensive relative to those in the EPI systems of low-income countries. The current single-dose presentation costs more to store in the cold chain relative to multi-dose presentations but also has lower wastage rates. It is, therefore, important to determine the optimal balance of vial size and storage costs after adjusting for wastage. Objectives: To project the cost implications of wastage when vaccine wastage rates vary across vial sizes using country specific wastage data. Methods: For each potential vial size, we estimated cold chain costs and the cost of wasted vaccine doses using country level wastage data and projections of the price per dose of vaccine and cold chain storage. Results: Only 19 (26%) of 72 GAVI eligible countries had analyzable wastage data at WHO/HQ. The median wastage rates for single, 2- and 10-dose vials were 5%, 7% and 10% respectively. However wastage varied between 1%-10%, 1%-27% and 4%-44% for single, 2- and 10-dose vials respectively. The increased variance for multi-dose vial wastage implied wastage costs potentially greater than the savings realized from lower storage volumes. Conclusions: The optimal vial-size for PCV is dependent upon country specific wastage rates but few countries have these data. There may be a role for both single and multi-dose vials that is best determined by local management and storage capacities making local wastage data critical. Without effective wastage monitoring and control there is a risk that wastage costs will possibly exceed the savings from multi-dose vials’ lower storage costs

Topics: RA Public aspects of medicine
Publisher: Landes Bioscience
Year: 2010
DOI identifier: 10.4161/hv.6.3.10397
OAI identifier:
Provided by: LSE Research Online

Suggested articles


  1. (2006). Available at: Accessed
  2. (2007). Available at: vaccine_quality/pqs_prequalified_devices/en/index. html. Accessed
  3. (2007). Financial Sustainability Plans: Kenya. Available at: en/index.html. Accessed
  4. (2006). GAVI Alliance Investment Case: Accelerating the Introduction of Pneumococcal Vaccines into GAVI-Eligible Countries.
  5. (2003). Introducing auto-disable syringes to the national immunization programme in Madagascar. Bull World Health Organ
  6. (2005). Introducing hepatitis B virus vaccine into the Expanded Programme on Immunization in Bangladesh: a proposed method to evaluate whether the existing infrastructure has the capacity. J Health Popul Nutr
  7. (2002). Organization. Guideline for Establishing or Improving Primary and Intermediate Vaccine Store.
  8. (2002). Organization. Guidelines for estimating costs of introducing new vaccines into the national immunization system.
  9. (1999). Organization. Pneumococcal vaccines: WHO position paper. doi
  10. (2001). Organization. Vaccine volume calculator: an aid for the introduction of new vaccines.
  11. (2007). Preventable Diseases Monitoring System: doi
  12. (2005). The costs of home delivery of a birth dose of hepatitis B vaccine in a prefilled syringe in Indonesia. Bull World Health Organ
  13. WHO Regional Office for South East Asia. Report on a Vaccine Wastage Study Conducted

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.